Linus Spatz

General San Martin, B, Argentina

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 9 publications

Serology as an early diagnostic tool in pediatric patients with Shiga toxin-producing Escherichia coli-associated hemolytic uremic syndrome: a post hoc analysis of a phase 2 clinical trial.

Serology as an early diagnostic tool in pediatric patients with Shiga toxin-producing Escherichia coli-associated hemolytic uremic syndrome: a post hoc analysis of a phase 2 clinical trial.

Journal: Journal of clinical microbiology

Published: February 27, 2026

INM004: Polyclonal Neutralizing Antibodies Against Shiga Toxin as a Treatment for Hemolytic Uremic Syndrome.

INM004: Polyclonal Neutralizing Antibodies Against Shiga Toxin as a Treatment for Hemolytic Uremic Syndrome.

Journal: Toxins

Published: March 29, 2025

Open-label, controlled, phase 2 clinical trial assessing the safety, efficacy, and pharmacokinetics of INM004 in pediatric patients with Shiga toxin-producing Escherichia coli-associated hemolytic uremic syndrome.

Open-label, controlled, phase 2 clinical trial assessing the safety, efficacy, and pharmacokinetics of INM004 in pediatric patients with Shiga toxin-producing Escherichia coli-associated hemolytic uremic syndrome.

Journal: Pediatric nephrology (Berlin, Germany)

Published: July 16, 2024

A phase I study to evaluate the safety, tolerance and pharmacokinetics of anti-Shiga toxin hyperimmune equine F (ab')2 fragments in healthy volunteers.

A phase I study to evaluate the safety, tolerance and pharmacokinetics of anti-Shiga toxin hyperimmune equine F (ab')2 fragments in healthy volunteers.

Journal: British journal of clinical pharmacology

Published: July 13, 2023

Surveillance of Shiga toxin-producing Escherichia coli associated bloody diarrhea in Argentina.

Surveillance of Shiga toxin-producing Escherichia coli associated bloody diarrhea in Argentina.

Journal: Revista Argentina de microbiologia

Published: July 19, 2022

Safety and effectiveness of RBD-specific polyclonal equine F(ab´)2 fragments for the treatment of hospitalized patients with severe Covid-19 disease: A retrospective cohort study.

Safety and effectiveness of RBD-specific polyclonal equine F(ab´)2 fragments for the treatment of hospitalized patients with severe Covid-19 disease: A retrospective cohort study.

Journal: PloS one

Published: May 12, 2022

RBD-specific polyclonal F(ab´)2 fragments of equine antibodies in patients with moderate to severe COVID-19 disease: A randomized, multicenter, double-blind, placebo-controlled, adaptive phase 2/3 clinical trial.

RBD-specific polyclonal F(ab´)2 fragments of equine antibodies in patients with moderate to severe COVID-19 disease: A randomized, multicenter, double-blind, placebo-controlled, adaptive phase 2/3 clinical trial.

Journal: EClinicalMedicine

Published: January 20, 2021

Development of a hyperimmune equine serum therapy for COVID-19 in Argentina.

Development of a hyperimmune equine serum therapy for COVID-19 in Argentina.

Journal: Medicina

Published: July 14, 2020

Susceptibility of wild populations of Biomphalaria spp. from neotropical South America to Schistosoma mansoni and interference of Zygocotyle lunata.

Susceptibility of wild populations of Biomphalaria spp. from neotropical South America to Schistosoma mansoni and interference of Zygocotyle lunata.

Journal: The Journal of parasitology

Published: April 25, 2012

Showing 1-9 of 9

Last Updated: 09/26/2026